Laboratory of Integrative Cancer Immunology, INSERM, Paris, France.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Oncotarget. 2022 Jan 5;13:18-31. doi: 10.18632/oncotarget.28100. eCollection 2022.
Because of the function and anatomical environment of the rectum, therapeutic strategies for local advanced rectal cancer (LARC) must deal with two challenging stressors that are a high-risk of local and distal recurrences and a high-risk of poor quality of life (QoL). Over the last three decades, advances in screening tests, therapies, and combined-modality treatment options and strategies have improved the prognosis of patients with LARC. However, owing to the heterogeneous nature of LARC and genetic status, the patient may not respond to a specific therapy and may be at increased risk of side-effects without the life-prolonging benefit. Indeed, each therapy can cause its own side-effects, which may worsen by a combination of treatments resulting in long-term poor QoL. In LARC, QoL has become even more essential with the increasing incidence of rectal cancer in young individuals. Herein, we analyzed the value of the Immunoscore-Biopsy (performed on tumor biopsy at diagnosis) in predicting outcomes, alone or in association with clinical and imaging data, for each therapy used in LARC.
由于直肠的功能和解剖环境，局部晚期直肠癌（LARC）的治疗策略必须应对两个具有挑战性的问题，即局部和远端复发的高风险以及生活质量（QoL）差的高风险。在过去的三十年中，筛查测试、治疗方法以及联合治疗选择和策略的进步改善了 LARC 患者的预后。然而，由于 LARC 的异质性和遗传状态，患者可能对特定的治疗方法没有反应，并且在没有延长生命益处的情况下，可能会增加副作用的风险。事实上，每种治疗方法都会引起自身的副作用，而联合治疗可能会导致长期生活质量较差。在 LARC 中，随着直肠癌在年轻人中的发病率不断增加，生活质量变得更加重要。在这里，我们分析了免疫评分-活检（在诊断时对肿瘤活检进行检测）的价值，以单独或与临床和影像学数据一起，预测 LARC 中每种治疗方法的疗效。
